Parexel

More big pharmaceuticals join trend of partnering with CROs to cut costs, speed drug development

Monday, October 11, 2010 10:27 AM

Major pharmaceutical companies are increasingly forming long-term, strategic partnerships with a small number of global contract research organizations (CROs) in order to cut costs and streamline their outsourced clinical work.

More... »

Parexel introduces temperature control process

Monday, August 30, 2010 09:02 AM

Parexel International of Boston, a global biopharmaceutical services company, has introduced an integrated temperature recording solution for study drug transportation as part of its expanded Clinical Logistics Services. Its temperature control process saves 24 to 48 hours over traditional cold chain methods in which temperature devices shipped out to investigative sites need to be transported back to a hub to be read out and analyzed before study drugs can be released for use. A central hub receives and disseminates confirmations of temperature data in real-time, allowing clinical site investigators to quickly begin using study drugs according to trial protocols. Working in cooperation with Stora Enso, a global paper, packaging and wood products company, and MediXine, specializing in multimodal communication e-services for health care and wellness, Parexel has developed a temperature recording process specifically designed and optimized for the clinical trial supply process. The packaging container for study drugs incorporates a Radio-Frequency Identification (RFID) tag for temperature recording and a dedicated compartment for a mobile phone, providing automatic tracking and remote, high-speed transmission of the complete temperature record. The RFID tag records study drug temperature at pre-defined time points, while a mobile phone application and web-based portal allow secure, controlled data transmission and access to temperature data in real-time between a central hub and an investigative site.

More... »

Parexel Hires Former FDA, MHRA Regulators

Tuesday, June 22, 2010 10:01 AM

Parexel Consulting, a business unit of Parexel International, has appointed former regulators Toby Silverman, M.D. and Keith Watson, Ph.D. as principal consultants.

More... »

Parexel Adds Two Locations in China

Thursday, May 27, 2010 09:11 AM

Parexel has opened two new offices in China, increasing its presence in the Asia-Pacific region to 17 locations, in order to meet growing demand for clinical development and regulatory consulting services from drug sponsors looking for more opportunities to include China in global drug development strategies.

More... »

Parexel Profits Rebound in Q3

Wednesday, April 28, 2010 07:12 AM

Parexel came back from a tough second quarter with strong third quarter results, posting a 10.1% increase in service revenues. The CRO, whose year-over-year profits were cut in half in the second quarter due to a cancelled project, reported revenues of $291.2 million in Q3, compared with $264.5 million for the same period last year.

More... »

Parexel Releases eClinical Platform for Late-Stage Clinical Trials

Tuesday, April 13, 2010 07:26 AM

Parexel, a CRO, released a new web-based platform to be used in late-phase clinical research to help users meet regulatory guidelines and ensure high quality data. The new product combines the expertise of Parexel’s existing Peri Approval Clinical Excellence (PACE) team with the eClinical capabilities of Perceptive Informatics, Parexel’s technology subsidiary. The platform allows for a variety of eClinical services, such as clinical trial management systems, electronic data capture, randomization and trial supply management, and electronic patient-reported outcomes, to be incorporated in late-phase studies.

More... »

Parexel Opens Third Early-Phase Unit in South Africa

Friday, February 26, 2010 12:49 PM

Parexel opened a new early phase unit in Port Elizabeth, South Africa, giving the contract research organization (CRO) its third early-phase facility in that country.

More... »

Parexel Reports 33% Drop in Income, Ups Guidance

Tuesday, January 26, 2010 07:14 AM

Parexel’s second quarter net income fell 33% to $3.5 million, or $0.06 per diluted share, compared with the same quarter last year.

More... »

Parexel Launches Expert Office

Friday, November 13, 2009 07:50 AM

Parexel has established The Expert Office, which provides a single point of contact for clients to more quickly access the company’s worldwide clinical research expertise.

More... »

Parexel's Q1 Revenue, Net Income Slips

Wednesday, October 28, 2009 07:21 AM

Parexel's first quarter consolidated service revenue dipped 1.2% to $259.8 million, compared with $263 million in the prior year period. Net income also slipped to $12.4 million, or $0.21 per diluted share, compared with net income of $13.6 million, or $0.23 per diluted share, for the year ago quarter.

More... »